US2735799A - Epinephrine ointment and method of - Google Patents
Epinephrine ointment and method of Download PDFInfo
- Publication number
- US2735799A US2735799A US2735799DA US2735799A US 2735799 A US2735799 A US 2735799A US 2735799D A US2735799D A US 2735799DA US 2735799 A US2735799 A US 2735799A
- Authority
- US
- United States
- Prior art keywords
- epinephrine
- ointment
- oxidant
- particles
- physiologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005139 epinephrine Drugs 0.000 title claims description 136
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 title claims description 134
- 239000002674 ointment Substances 0.000 title claims description 82
- 239000002245 particle Substances 0.000 claims description 48
- 239000003963 antioxidant agent Substances 0.000 claims description 46
- 235000006708 antioxidants Nutrition 0.000 claims description 46
- 230000003078 antioxidant Effects 0.000 claims description 40
- 239000003883 ointment base Substances 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- -1 EPINEPHRINE COMPOUND Chemical class 0.000 claims description 14
- 239000003981 vehicle Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 230000003647 oxidation Effects 0.000 claims description 12
- 238000007254 oxidation reaction Methods 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 48
- 229940075579 Propyl Gallate Drugs 0.000 description 22
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 22
- 235000010388 propyl gallate Nutrition 0.000 description 22
- 239000000473 propyl gallate Substances 0.000 description 22
- 208000003251 Pruritus Diseases 0.000 description 14
- 239000002480 mineral oil Substances 0.000 description 14
- 235000010446 mineral oil Nutrition 0.000 description 14
- 239000004264 Petrolatum Substances 0.000 description 12
- 229940066842 Petrolatum Drugs 0.000 description 12
- 238000001704 evaporation Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 235000019271 petrolatum Nutrition 0.000 description 12
- 210000003491 Skin Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000000111 anti-oxidant Effects 0.000 description 6
- 238000002845 discoloration Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 4
- YLXIPWWIOISBDD-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound OC(=O)C(O)C(O)C(O)=O.CNCC(O)C1=CC=C(O)C(O)=C1 YLXIPWWIOISBDD-UHFFFAOYSA-N 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N Benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- 229960005274 Benzocaine Drugs 0.000 description 4
- 229940108066 Coal Tar Drugs 0.000 description 4
- 208000006641 Skin Disease Diseases 0.000 description 4
- 241000159243 Toxicodendron radicans Species 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000011280 coal tar Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 229960003157 epinephrine bitartrate Drugs 0.000 description 4
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000001590 oxidative Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001681 protective Effects 0.000 description 4
- 239000011253 protective coating Substances 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- ZNMXKJDERFMXNF-ZETCQYMHSA-N (1R)-1-(2-hydroxy-1,3,2-benzodioxaborol-5-yl)-2-(methylamino)ethanol Chemical compound CNC[C@H](O)C1=CC=C2OB(O)OC2=C1 ZNMXKJDERFMXNF-ZETCQYMHSA-N 0.000 description 2
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 208000010247 Contact Dermatitis Diseases 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 208000005679 Eczema Diseases 0.000 description 2
- AELFRHHZGTVYGJ-QMMMGPOBSA-N Epinephrine sulfate Chemical compound CNC[C@H](O)C1=CC=C(OS(O)(=O)=O)C(O)=C1 AELFRHHZGTVYGJ-QMMMGPOBSA-N 0.000 description 2
- 210000000245 Forearm Anatomy 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 229960001295 Tocopherol Drugs 0.000 description 2
- 208000001319 Vasomotor Rhinitis Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229940046009 Vitamin E Drugs 0.000 description 2
- 230000001464 adherent Effects 0.000 description 2
- 230000003444 anaesthetic Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000002978 anti-vasoconstrictor Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 231100000080 dermatitis contact Toxicity 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 231100001003 eczema Toxicity 0.000 description 2
- 229960001772 epinephrine sulfate Drugs 0.000 description 2
- PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 201000009053 neurodermatitis Diseases 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229930003799 tocopherols Natural products 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- My present invention relates, generally, to novel therapeutic compositions and methods of making the same wherein epinephrine, either as the base or as one of the physiologically active salts, is protected and stabilized against oxidation.
- the invention relates more particularly to epinephrine ointments and ointment bases, and methods of preparing the same, wherein epinephrine is protected against oxidation so that the epinephrine activity remains unimpaired for extended periods under ordinary storage conditions.
- Epinephrine base and its physiologically active salts or derivatives such as epinephrine hydrochloride, epinephrine bitartrate, epinephrine. sulfate and epinephrine borate, are notable for theease with which they decompose or deteriorate.
- Epinephrine compounds are particularly sensitive to heat and to deterioration by oxidation and exposure to light also tends to hasten decomposition, which is manifested by discoloration or browning of the compounds which are white when in a pure and fresh condition.
- epinephrine compounds are normally packaged and distributed in nitrogen-filled glassampoules in the absence of oxygen. Epinephrine compounds cannot withstand heating and therefore heating of epinephrine compounds is to be avoided.
- the method of this invention involves first dissolving a suitable anti-oxidant in a liquid which is a solvent for the anti-oxidant but in which epinephrine base or its medically useful compounds are insoluble. After such an anti-oxidant solution has been prepared, the epinephrine in powdered form is uniformly dispersed in the solution and the solvent is then evaporated, preferably under reduced pressure without heating.
- Drying is discontinued before all of the solvent has completely evaporated so as to leave the residue in a condition in which it is not completely dry or cake solid.
- the preferred condition of the residue is one which permits it to be easily dispersed and suspended in an oily vehicle such as mineral oil or petrolatum.
- An ointment or ointment base prepared in this manner and packed in ordinary medical tins will retain its full physiological activity without noticeable deterioration or discoloration at temperatures up to 50 C. for well over a month, and at ordinary room temperatures for well over a year.
- An object of the invention is a practical and convenient method whereby medically useful uniform suspensions and dispersions of epinephrine, either as the base or its various physiologically active salts, in oils and ointments may be made and an anti-oxidant for the epinephrine compound incorporated in such a manner that the preparations re- 2 ,735,799 Patented Feb. 21, 1956 tain substantially full epinephrine potency for prolonged periods at ordinary temperatures and conditions.
- An object of the present invention is the provision of a method whereby, and compositions wherein, epinephrine in its various physiological forms is stabilized against oxidative-deterioration or spoilage without being packaged in oxygen-free, nitrogen-filled containers or ampoules.
- Another object of the invention is the provision of ointments and ointment bases containing epinephrine in one of its physiological forms, which ointments are producible by a convenient, inexpensive method and are safe to use and retain full potency for prolonged periods when stored in ordinary containers such as medical tins or collapsible tubes.
- Another object of the invention is the provision of an epinephrine ointment for oil base wherein the epinephrine content is stabilized and protected against oxidation and deterioration due to exposure to air and light and which oils or ointment bases may be used as such or mixed with other ointments or constituents such as coal tar ointments and anesthetic ointments such as benzocaine ointment.
- Still another object of the invention is the provision of epinephrine ointments which are biologically and physiologically active to relieve itching and inflammation on the human skin by virtue of their anti-histaminic and vasoconstrictor actions, and which ointments retain their activity for prolonged periods of time when stored under ordinary conditions in ordinary type containers.
- the mixture was removed from the disintegrator and placed in a vacuum chamber equipped with a suitable agitator whereby the mixture could be agitated for uniformity while the ether was being evaporated at room temperature. Before the ether had been completely volatilized and removed, drying was discontinued when the residue was slightly moist and not yet hardened or completely dried.
- the paste was gently pulverized into particles of epinephrine coated with and encased in propyl gallate. Such protective sheaths or coatings of the anti-oxidant formed around the epinephrine particles during evaporation.
- Example 2 30 grams of the epinephrine ointment base prepared in accordance with Example 1 was intimately blended with 30 grams of coal tar ointment. The resulting ointment is adapted for treatment of eczema.
- Example 3 30 grams of the ointment base prepared in accordance with Example 1 was blended with 30 grams of petrolatum so as to produce an ointment having an epinephrine concentration of l to 1,000 and the resulting ointment was found to be of value in the treatment of pruritis ani, pruritis vulvae, allergic dermatitis, poison ivy and other similar itching dermatoses of the skin where the skin was broken. This ointment was also of value in the treatment of vasomotor rhinitis. This ointment was placed in ordinary ointment tins and tested for shelf life stability.
- Controls were prepared by duplicating the procedure of Example 1 except that no propyl gallate or other antioxidant was dissolved in the ether.
- the ointments prepared with the use of the propyl gallate showed stability at 50 C. for at least one month whereas'the controls turned brown and discolored after only a few days standing at this temperature. After standing for two months at 50 C. the ointments prepared using the propyl gallate anti-oxidant showed only a very slight tinge of brown. Tins of the ointment which were stored at room temperatures retained their activity without showing any appreciable discoloration for periods in excess of one year.
- the epinephrine activity of the various ointments was tested by making scratches on the anterior aspect of the forearm with a binocular loupe and then applying the ointments to the scratches.
- the ointments undergoing test evalution were applied to one scratch and a freshly prepared control ointment was applied to an adjacent scratch and the blanching reactions observed.
- This is a delicate and sensitive test for epinephrine stability since Example 4 30 grams of the epinephrine ointment base prepared in accordance with Example 1 was uniformly and intimately blended with 30 grams of benzocaine ointment.
- the ointment product obtained was useful in the treatment of pruritus due to dermatoses where the skin is broken,
- the epinephrine base USP may be replaced with equivalent quantities of epinephrine hydrochloride, epinephrine bitartrate or epinephrine sulfate.
- the propyl gallate may be replaced by other anti-oxidants which are soluble in the organic liquids used such as ether.
- ether in Example 1 may be replaced by other solvents such as acetone, chloroform or other compatible volatile solvent.
- the mineral oil in Example 1 may be replaced by vegetable oils such as refined castor oil, peanut oil or olive oil. While petrolatum is the preferred ointment base or vehicle, it can be replaced in whole or in part by other ointment bases such as low melting parafiins and substantially water-free vanishing creams.
- the anti-oxidants which are in solution form adherent protective coatings or sheaths around each particle of the epinephrine compound so as to keep the epinephrine out of contact with oxygen.
- These sheaths seem to remain intact to a considerable extent even when the resulting coated particles of the epinephrine are dispersed in the oils or ointment bases.
- the method of preparing an oleaginous epinephrine composition which may be exposed to air without substantial loss of epinephrine potency which comprises, dispersing particles of a physiologically active epinephrine compound in a solution of an organic anti-oxidant in an organic solvent in which solution the epinephrine is substantially insoluble, vaporizing the solvent so as to form a solid residue of particles composed of epinephrine and said organic anti-oxidant, and uniformly blending said residue in an oleaginous vehicle.
- the method of preparing an oleaginous epinephrine composition which may be exposed to the atmosphere without substantial loss of epinephrine potency which comprises, dispersing particles of a physiologically active epinephrine compound in a solution of an organic antioxidant in a volatile organic solvent in which the epinephrine is substantially insoluble, evaporating substantially all of said solvent but discontinuing evaporation before it is complete so as to form a residue which is not completely dry, and uniformly blending said residue in an oleaginous vehicle.
- the method of preparing an epinephrine ointment which is relatively stable on exposure to air comprises, dispersing particles of a physiologically active epinephrine compound in a solution of an epinephrine protecting organic anti-oxidant dissolved in a volatile organic solvent in which the epinepherine is substantially insoluble, evaporating said solvent just short of dryness, and uniformly blending the resulting residue in an ointment base.
- the method of preparing an epinephrine ointment which retains its potency when exposed to the atmosphere comprises, dispersing particles of physiologically active epinephrine in a solution of propyl gallate in ether, evaporating the ether to form a solid residue of particles composed of epinephrine and propyl gallate, uniformly suspending said residue in mineral oil, and blending the mineral oil suspension into petrolatum.
- Epinephrine ointment which is stable to oxidation comprising particles composed of physiologically active epinephrine and an organic anti-oxidant substance uniformly dispersed throughout an ointment base, said ointment being prepared substantially according to the method of claim 1.
- Epinephrine ointment stabilized against oxidative deterioration comprising particles composed of physiologically active epinephrine and propyl gallate uniformly dispersed throughout an ointment vehicle, said ointment being prepared substantially according to the method of claim 2.
- Epinephrine ointment stabilized, against oxidative deterioration comprising particles composed of physiologi- Wilhelm Mar. 13, 1934 Taylor Oct. 22, 1940 6 OTHER REFERENCES I. Pharmacy and Pharmacology, Nov. 1949, pages 774-776.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Description
United States Patent EPINEPHRINE OINTMENT AND METHOD OF PREPARATION THEREOF Harold A. Abramson, New York, N. Y.
No Drawing. Application February 18, 1953, Serial No. 337,679
8 Claims. (Cl. 167-63) My present invention relates, generally, to novel therapeutic compositions and methods of making the same wherein epinephrine, either as the base or as one of the physiologically active salts, is protected and stabilized against oxidation. The invention relates more particularly to epinephrine ointments and ointment bases, and methods of preparing the same, wherein epinephrine is protected against oxidation so that the epinephrine activity remains unimpaired for extended periods under ordinary storage conditions.
Epinephrine base and its physiologically active salts or derivatives, such as epinephrine hydrochloride, epinephrine bitartrate, epinephrine. sulfate and epinephrine borate, are notable for theease with which they decompose or deteriorate. Epinephrine compounds are particularly sensitive to heat and to deterioration by oxidation and exposure to light also tends to hasten decomposition, which is manifested by discoloration or browning of the compounds which are white when in a pure and fresh condition.
Because of the instability of epinephrine on exposure to air, epinephrine compounds are normally packaged and distributed in nitrogen-filled glassampoules in the absence of oxygen. Epinephrine compounds cannot withstand heating and therefore heating of epinephrine compounds is to be avoided.
I have found in accordance with the present invention a method by which medically useful epinephrine compounds may be provided with a protective coating of antioxidant films in such a manner that the epinephrine may be uniformly dispersed and suspended in oily vehicles such as mineral oil, sesame oil, or petrolatum and retain full stability for prolonged periods. The method of this invention involves first dissolving a suitable anti-oxidant in a liquid which is a solvent for the anti-oxidant but in which epinephrine base or its medically useful compounds are insoluble. After such an anti-oxidant solution has been prepared, the epinephrine in powdered form is uniformly dispersed in the solution and the solvent is then evaporated, preferably under reduced pressure without heating. Dryingis discontinued before all of the solvent has completely evaporated so as to leave the residue in a condition in which it is not completely dry or cake solid. The preferred condition of the residue is one which permits it to be easily dispersed and suspended in an oily vehicle such as mineral oil or petrolatum. An ointment or ointment base prepared in this manner and packed in ordinary medical tins will retain its full physiological activity without noticeable deterioration or discoloration at temperatures up to 50 C. for well over a month, and at ordinary room temperatures for well over a year.
An object of the invention is a practical and convenient method whereby medically useful uniform suspensions and dispersions of epinephrine, either as the base or its various physiologically active salts, in oils and ointments may be made and an anti-oxidant for the epinephrine compound incorporated in such a manner that the preparations re- 2 ,735,799 Patented Feb. 21, 1956 tain substantially full epinephrine potency for prolonged periods at ordinary temperatures and conditions.
An object of the present invention is the provision of a method whereby, and compositions wherein, epinephrine in its various physiological forms is stabilized against oxidative-deterioration or spoilage without being packaged in oxygen-free, nitrogen-filled containers or ampoules.
Another object of the invention is the provision of ointments and ointment bases containing epinephrine in one of its physiological forms, which ointments are producible by a convenient, inexpensive method and are safe to use and retain full potency for prolonged periods when stored in ordinary containers such as medical tins or collapsible tubes.
Another object of the invention is the provision of an epinephrine ointment for oil base wherein the epinephrine content is stabilized and protected against oxidation and deterioration due to exposure to air and light and which oils or ointment bases may be used as such or mixed with other ointments or constituents such as coal tar ointments and anesthetic ointments such as benzocaine ointment.
' Still another object of the invention is the provision of epinephrine ointments which are biologically and physiologically active to relieve itching and inflammation on the human skin by virtue of their anti-histaminic and vasoconstrictor actions, and which ointments retain their activity for prolonged periods of time when stored under ordinary conditions in ordinary type containers.
Certain other objects of the invention will, in part, be obvious and will, in part, appear hereinafter.
For a more complete understanding of the nature and scope of the invention, reference may be had to the fol- Example 1 0.1 gram of propyl gallate was dissolved in 20 grams of ether (USP grade). 1 gram of epinephrine (USP) having a particle size of approximately 10 microns or below was added to the ether solution of propyl gallate and the mixture was placed in a tuning fork disintegrator (or a colloid mill or other known type of disintegrator or blender). The solution was left in the disintegrator for approximately 2 minutes during which time the glass beads in the disintegrator sub-divided the clusters of the epinephrine powder into individual particles and reduced the particle size of the individual particles somewhat. The mixture was removed from the disintegrator and placed in a vacuum chamber equipped with a suitable agitator whereby the mixture could be agitated for uniformity while the ether was being evaporated at room temperature. Before the ether had been completely volatilized and removed, drying was discontinued when the residue was slightly moist and not yet hardened or completely dried. The paste was gently pulverized into particles of epinephrine coated with and encased in propyl gallate. Such protective sheaths or coatings of the anti-oxidant formed around the epinephrine particles during evaporation. These particles were suspended in 50 grams of mineral oil and uniformly distributed therein by placing in a known type of blender or disintegrator such as a ball mill, Waring Blendor or a tuning fork disintegrator. The uniform suspension of the epinephrine particles in mineral oil was then uniformly blended with 500 grams of petrolatum to provide an ointment base having an epinephrine concentration of 1 to 500.
Example 2 30 grams of the epinephrine ointment base prepared in accordance with Example 1 was intimately blended with 30 grams of coal tar ointment. The resulting ointment is adapted for treatment of eczema.
Example 3 30 grams of the ointment base prepared in accordance with Example 1 was blended with 30 grams of petrolatum so as to produce an ointment having an epinephrine concentration of l to 1,000 and the resulting ointment was found to be of value in the treatment of pruritis ani, pruritis vulvae, allergic dermatitis, poison ivy and other similar itching dermatoses of the skin where the skin was broken. This ointment was also of value in the treatment of vasomotor rhinitis. This ointment was placed in ordinary ointment tins and tested for shelf life stability. Controls were prepared by duplicating the procedure of Example 1 except that no propyl gallate or other antioxidant was dissolved in the ether. The ointments prepared with the use of the propyl gallate showed stability at 50 C. for at least one month whereas'the controls turned brown and discolored after only a few days standing at this temperature. After standing for two months at 50 C. the ointments prepared using the propyl gallate anti-oxidant showed only a very slight tinge of brown. Tins of the ointment which were stored at room temperatures retained their activity without showing any appreciable discoloration for periods in excess of one year.
The epinephrine activity of the various ointments was tested by making scratches on the anterior aspect of the forearm with a binocular loupe and then applying the ointments to the scratches. The ointments undergoing test evalution were applied to one scratch and a freshly prepared control ointment was applied to an adjacent scratch and the blanching reactions observed. This is a delicate and sensitive test for epinephrine stability since Example 4 30 grams of the epinephrine ointment base prepared in accordance with Example 1 was uniformly and intimately blended with 30 grams of benzocaine ointment. The ointment product obtained was useful in the treatment of pruritus due to dermatoses where the skin is broken,
poison ivy, contact dermatitis, pruritis ani, pruritis vulvae and neurodermatitis.
A number of modifications and substitutions may be made in the foregoing examples. Thus, the epinephrine base USP may be replaced with equivalent quantities of epinephrine hydrochloride, epinephrine bitartrate or epinephrine sulfate. The propyl gallate may be replaced by other anti-oxidants which are soluble in the organic liquids used such as ether. Thus, butylated hydroxyanisole, tocopherol (vitamin E), ethyl thioglycollate, and other oil-soluble anti-oxidants may be used in lieu of the propyl gallate in Example 1. In like manner, the ether in Example 1 may be replaced by other solvents such as acetone, chloroform or other compatible volatile solvent.
The mineral oil in Example 1 may be replaced by vegetable oils such as refined castor oil, peanut oil or olive oil. While petrolatum is the preferred ointment base or vehicle, it can be replaced in whole or in part by other ointment bases such as low melting parafiins and substantially water-free vanishing creams.
Apparently, when the suspensions of epinephrine in the anti-oxidant solutions are evaporated in accordance with the method described in Example 1, the anti-oxidants which are in solution form adherent protective coatings or sheaths around each particle of the epinephrine compound so as to keep the epinephrine out of contact with oxygen. These sheaths seem to remain intact to a considerable extent even when the resulting coated particles of the epinephrine are dispersed in the oils or ointment bases. Improved results are obtained when the antioxidant solutions containing the dispersions of epinephrine are not evaporated to complete dryness but are allowed to retain a small residual amount of the volatile solvent thereby preventing the anti-oxidant coated particles of epinephrine from adhering one to another and forming a non-suspendable film or deposit.
Having fully disclosed my invention and set forth preferred embodiments thereof, what is claimed as new is:
l. The method of preparing an oleaginous epinephrine composition which may be exposed to air without substantial loss of epinephrine potency which comprises, dispersing particles of a physiologically active epinephrine compound in a solution of an organic anti-oxidant in an organic solvent in which solution the epinephrine is substantially insoluble, vaporizing the solvent so as to form a solid residue of particles composed of epinephrine and said organic anti-oxidant, and uniformly blending said residue in an oleaginous vehicle.
2. The method of preparing an oleaginous epinephrine composition which may be exposed to the atmosphere without substantial loss of epinephrine potency which comprises, dispersing particles of a physiologically active epinephrine compound in a solution of an organic antioxidant in a volatile organic solvent in which the epinephrine is substantially insoluble, evaporating substantially all of said solvent but discontinuing evaporation before it is complete so as to form a residue which is not completely dry, and uniformly blending said residue in an oleaginous vehicle.
3. The method of preparing an epinephrine ointment which is relatively stable on exposure to air which comprises, dispersing particles of a physiologically active epinephrine compound in a solution of an epinephrine protecting organic anti-oxidant dissolved in a volatile organic solvent in which the epinepherine is substantially insoluble, evaporating said solvent just short of dryness, and uniformly blending the resulting residue in an ointment base.
4. The method of preparing an epinephrine ointment which comprises, dispersing particles of physiologically active epinephrine compound in a solution of an epinephrine protective organic anti-oxidant dissolved in ether, evaporating the ether so as to form a residue which may be pulverized and contains a small amount of ether, uniformly suspending said residue in oil, and blending the resulting oil mixture into an ointment base.
5. The method of preparing an epinephrine ointment which retains its potency when exposed to the atmosphere which comprises, dispersing particles of physiologically active epinephrine in a solution of propyl gallate in ether, evaporating the ether to form a solid residue of particles composed of epinephrine and propyl gallate, uniformly suspending said residue in mineral oil, and blending the mineral oil suspension into petrolatum.
6. Epinephrine ointment which is stable to oxidation comprising particles composed of physiologically active epinephrine and an organic anti-oxidant substance uniformly dispersed throughout an ointment base, said ointment being prepared substantially according to the method of claim 1.
7. Epinephrine ointment stabilized against oxidative deterioration comprising particles composed of physiologically active epinephrine and propyl gallate uniformly dispersed throughout an ointment vehicle, said ointment being prepared substantially according to the method of claim 2.
8. Epinephrine ointment stabilized, against oxidative deterioration comprising particles composed of physiologi- Wilhelm Mar. 13, 1934 Taylor Oct. 22, 1940 6 OTHER REFERENCES I. Pharmacy and Pharmacology, Nov. 1949, pages 774-776.
Gutman: Modern Drug Encyclopedia and Therapeutic 5 Guide, pages 14, 15, New Modern Drugs, N. Y., 1941.
Claims (2)
1. THE METHOD OF PREPARING AN OLEAGINOUS EPINEPHRINE COMPOSITION WHICH MAY BE EXPOSED TO AIR WITHOUT SUBSTANTIAL LOSS OF EPINEPHRINE POTENCY WHICH COMPRISES, DISPERSING PARTICLES OF A PHYSIOLOGICALLY ACTIVE EPINEPHRINE COMPOUND IN A SOLUTION OF AN ORGANIC ANTI-OXIDANT IN AN ORGANIC SOLVENT IN WHICH SOLUTION THE EPINEPHRINE IS SUBSTANTIALLY INSOLUBLE, VAPORIZING THE SOLVENT SO AS TO FORM A SOLID RESIDUE OF PARTICLES COMPOSED OF EPINEPHRINE AND SAID ORGANIC ANTI-OXIDANT, AND UNIFORMLY BLENDING SAID RESIDUE IN AN OLEAGINOUS VEHICLE.
6. EPINEPHRINE OINTMENT WHICH IS STABLE TO OXIDATION COMPRISING PARTICLES COMPOSED OF PHYSIOLOGICALLY ACTIVE EPINEPHRINE AND AN ORGANIC ANTI-OXIDANT SUBSTANCE UNIFORMLY DISPERSED THROUGHOUT AN OINTMENT BASE, SAID OINTMENT BEING PREPARED SUBSTANTIALLY ACCORDING TO THE METHOD OF CLAIM 1.
Publications (1)
Publication Number | Publication Date |
---|---|
US2735799A true US2735799A (en) | 1956-02-21 |
Family
ID=3445173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US2735799D Expired - Lifetime US2735799A (en) | Epinephrine ointment and method of |
Country Status (1)
Country | Link |
---|---|
US (1) | US2735799A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0267051A2 (en) * | 1986-11-07 | 1988-05-11 | Purepac, Inc. | Transdermal administration of amines |
US5422118A (en) * | 1986-11-07 | 1995-06-06 | Pure Pac, Inc. | Transdermal administration of amines with minimal irritation and high transdermal flux rate |
US20030106824A1 (en) * | 2001-11-02 | 2003-06-12 | Meridian Medical Technologies, Inc. | Medicament container, a medicament dispensing kit for administering medication and a method for packaging the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1950956A (en) * | 1931-10-19 | 1934-03-13 | Marshall Field & Company | Method of coating chloramine and product thereof |
US2218592A (en) * | 1939-06-17 | 1940-10-22 | Atlantic Coast Fisheries Co | Vitamin preparation and method of making same |
-
0
- US US2735799D patent/US2735799A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1950956A (en) * | 1931-10-19 | 1934-03-13 | Marshall Field & Company | Method of coating chloramine and product thereof |
US2218592A (en) * | 1939-06-17 | 1940-10-22 | Atlantic Coast Fisheries Co | Vitamin preparation and method of making same |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0267051A2 (en) * | 1986-11-07 | 1988-05-11 | Purepac, Inc. | Transdermal administration of amines |
JPS63165330A (en) * | 1986-11-07 | 1988-07-08 | モレキュロン・インコーポレイテッド | Percutaneous administration of amine |
EP0267051A3 (en) * | 1986-11-07 | 1990-10-03 | Moleculon Inc. | Transdermal administration of amines |
US5422118A (en) * | 1986-11-07 | 1995-06-06 | Pure Pac, Inc. | Transdermal administration of amines with minimal irritation and high transdermal flux rate |
US20030106824A1 (en) * | 2001-11-02 | 2003-06-12 | Meridian Medical Technologies, Inc. | Medicament container, a medicament dispensing kit for administering medication and a method for packaging the same |
US7708719B2 (en) * | 2001-11-02 | 2010-05-04 | Meridian Medical Technologies, Inc. | Medicament container, a medicament dispensing kit for administering medication and a method for packaging the same |
US20100174268A1 (en) * | 2001-11-02 | 2010-07-08 | Meridian Medical Technologies, Inc. | Methods of venting, sealing, and dispensing from a medicament container |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6313169B1 (en) | Lutein esters having high bioavailability | |
US3849569A (en) | Composition containing procaine penicillin | |
KR920003331B1 (en) | Injectable composition contains spergualin of making method | |
DE4345199A1 (en) | Use of dihydrolipoic acid | |
JPS603044B2 (en) | vitamin supplements | |
EP0137978B1 (en) | Nitroester preparation for coronary therapy | |
KR20000076328A (en) | Stable extract of hypericum perforatum l., processes for its preparation and pharmaceutical compositions | |
IE47787B1 (en) | Viricidal substances and preparations and use thereof | |
US2735799A (en) | Epinephrine ointment and method of | |
WO2023179082A1 (en) | Drug coating medical instrument, preparation method therefor and use thereof, and drug coating and use thereof | |
DE69423528T2 (en) | Medicament containing Argatroban analogues | |
CN101791310A (en) | Vinpocetine medicine composition and preparation method thereof | |
CN108619097B (en) | Efficient anticancer and antioxidant composite liposome | |
US2487336A (en) | Penicillin product | |
DK165209B (en) | DIFFERENT DISPERSIONS FOR DELAYED RELEASE OF AN ORGANIC COMPOUND AND USE OF THE DISPERSIONS FOR THE PREPARATION OF A POWDER, A MOVIE OR ANOTHER ITEM | |
CN109908204A (en) | A kind of essential wind oil and its preparation process | |
EP1137440A1 (en) | A stable product of isohexylnaphthazarins with penta- and tetra-cyclic triterpenes | |
DE804927T1 (en) | Medicinal product containing multiantioxidant | |
KR102050070B1 (en) | Oil based composition having oxidation stability and soft capsules comprising the same | |
DE2534744A1 (en) | Stabilisation of oils, fats and vitamin compsns. - with antioxidant (1,4)-dihydro-pyridine derivs. | |
JPH054925A (en) | Soft capsule preparation of alpha calcidiol | |
US3449494A (en) | Anti-inflammatory compositions containing a corticoidal steroid and a testololactone | |
US3014902A (en) | Table | |
JP3640005B2 (en) | Soft capsule coating | |
US2832720A (en) | Vitamin compositions and method of preparing same |